Synthesis and antiviral activity of new 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), specific inhibitors of human immunodeficiency virus type 1.

• Published in: Antiviral Chemistry and Chemotherapy
• Main Authors: Silvio Massa, Antonello Mai, Marino Artico, Enzo Tramontano, Anna Giulia Loi, Patrizia Scano, Paolo La Colla, SBARDELLA, Gianluca
• Other Authors: Silvio, Massa, Antonello, Mai, Marino, Artico, Sbardella, Gianluca, Enzo, Tramontano, Anna Giulia, Loi, Patrizia, Scano, Paolo La, Colla
• Format: Article in Journal/Newspaper
• Language: English
• Published: 1995
• Subjects: AIDS chemotherapy; Anti-HIV agent; Dihydroalkoxybenzyloxopyrimidine; DABO; Nonnucleoside reverse transcriptase inhibitors (NNRTI); artico
• Online Access: http://hdl.handle.net/11386/3006544; https://doi.org/10.1177/095632029500600101; http://journals.sagepub.com/doi/10.1177/095632029500600101

3,4-Dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs) have emerged as non-nucleoside inhibitors of human immunodeficiency virus type 1 [Artico et al. (1993), Antiviral Chem Chemother 4: 361-368]. With a view to increasing their potency, a new series of DABO derivatives, differently substituted at positions C-2 and/or C-5 of the pyrimidine ring and 3' or 3',5' of the benzyl moiety, have been synthesized. DABOs were prepared by reacting O-methylisourea with the appropriate methyl 2-alkyl-4-phenylacetylacetate, with formation of 3,4-dihydro-2-methoxy-6-arylmethyl-4-oxoprimidines. Subsequent displacement of the methoxy group linked at the 2-position of the pyrimidine ring by treatment with alkoxy and cycloalkoxy potassium salts led to the required derivatives. In vitro, the most potent compounds were 12e and 12p, which had an EC(50) of 0.8 mu M and a selective index of 400.